Curis Lifesciences (NSE:CURIS) Notes Receivable: ₹0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:CURIS Curis Lifesciences Ltd NSE:CURIS
19 GF Score
Price ₹110.00
! 2 Warning Signs
View Full Analysis

What is Curis Lifesciences Notes Receivable?

Curis Lifesciences NSE:CURIS +0.09% 19 Notes Receivable is ₹0.0 Mil as of Mar. 2026. GuruFocus rates NSE:CURIS with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Curis Lifesciences's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0.0 Mil.

Curis Lifesciences Notes Receivable Related Terms

Curis Lifesciences Notes Receivable Historical Data

* Premium members only.

The historical data trend for Curis Lifesciences's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curis Lifesciences Notes Receivable Chart

Curis Lifesciences Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Notes Receivable
0.00 0.00 0.00 0.00

Curis Lifesciences Semi-Annual Data
Mar23 Mar24 Mar25 Mar26
Notes Receivable 0.00 0.00 0.00 0.00
NSE:CURIS
19GF Score
Curis Lifesciences Ltd NSE:CURIS
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curis Lifesciences Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0.0 Mil mean?
Curis Lifesciences (NSE:CURIS) has a Notes Receivable of ₹0.0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Curis Lifesciences and its competitors.
Is Curis Lifesciences' Notes Receivable too high?
Curis Lifesciences' current Notes Receivable is ₹0.0 Mil. Overall, Curis Lifesciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' Notes Receivable compare to ZTS and UTHR?
Curis Lifesciences' Notes Receivable of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Curis Lifesciences and its competitors. Curis Lifesciences's current Notes Receivable is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current Notes Receivable of ₹0.0 Mil. The current Notes Receivable is ₹0.0 Mil. Curis Lifesciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current Notes Receivable is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curis Lifesciences Business Description

Address PF-23, GIDC Sanand - II, Industrial Acme Pharma, Opposite Teva Pharma, Sanand, Ahmedabad, GJ, IND, 382110
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
19GF Score

Get the complete analysis for NSE:CURIS

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹110.00
Price